GlaxoSmithKline's (GSK) and Prosensa's (RNA) Drisapersen treatment for Duchenne Muscular Dystrophy fails to reach its primary goal in a Phase III trial of enabling a statistically significant improvement in the Six-Minute Walking Distance test vs a placebo.
Prosensa says it remains committed to the overall program and will continue to work closely with GSK.
GSK intends to complete a full evaluation of the benefit-to-risk profile of Drisapersen across all studies by the year-end. This could include analyses of pooled results from various Drisapersen studies.
Prosensa collapses 23% and GSK is +0.3%. Sarepta Therapeutics (SRPT), which is also developing a treatment for Duchenne Muscular Dystrophy, is +12.8%. (PR)